2023
A narrative review of non-racemic amisulpride (SEP-4199) for treatment of depressive symptoms in bipolar disorder and LB-102 for treatment of schizophrenia
Wu J, Kwan A, Rhee T, Ho R, d’Andrea G, Martinotti G, Teopiz K, Ceban F, McIntyre R. A narrative review of non-racemic amisulpride (SEP-4199) for treatment of depressive symptoms in bipolar disorder and LB-102 for treatment of schizophrenia. Expert Review Of Clinical Pharmacology 2023, 16: 1085-1092. PMID: 37864424, DOI: 10.1080/17512433.2023.2274538.Peer-Reviewed Original ResearchMeSH KeywordsAmisulprideAntidepressive AgentsAntipsychotic AgentsBipolar DisorderDepressionDepressive Disorder, MajorHumansSchizophreniaSulpirideConceptsDepressive symptomsSide effectsBipolar disorderRecent phase 2 trialsPhase 2 trialPhase 1 studyTreatment-resistant schizophreniaExtrapyramidal side effectsD2 receptor bindingReceptor-mediated effectsTreatment of schizophreniaMajor depressive disorderImproved treatment strategiesBipolar disorder IDevelopment of SEPAntidepressant effectsDepressive disorderTreatment strategiesPharmacological profileLow dosesNarrative reviewDisorder ISymptomsAmisulprideReceptor bindingEfficacy, safety, and tolerability of ulotaront (SEP-363856, a trace amine-associated receptor 1 agonist) for the treatment of schizophrenia and other mental disorders: a systematic review of preclinical and clinical trials
Le G, Gillissie E, Rhee T, Cao B, Alnefeesi Y, Guo Z, Di Vincenzo J, Jawad M, March A, Ramachandra R, Lui L, McIntyre R. Efficacy, safety, and tolerability of ulotaront (SEP-363856, a trace amine-associated receptor 1 agonist) for the treatment of schizophrenia and other mental disorders: a systematic review of preclinical and clinical trials. Expert Opinion On Investigational Drugs 2023, 32: 401-415. PMID: 37096491, DOI: 10.1080/13543784.2023.2206559.Peer-Reviewed Original ResearchConceptsTrace amine-associated receptor 1Long-term efficacyTreatment of schizophreniaClinical trialsSystematic reviewMental disordersNegative symptomsAdverse effectsAdverse effect profileCochrane Collaboration's toolRisk of biasInclusion/exclusion criteriaNovel therapeutic targetPubMed/MEDLINEQuality of lifeMechanism of actionAlternative treatment methodAtypical antipsychoticsEffect profileSimilar pathophysiologyCognitive dysfunctionPreclinical studiesExclusion criteriaOvid databasesTherapeutic target
2020
Changes in pharmacotherapeutic approaches in the treatment of bipolar disorder by primary care physicians
Rhee TG, Olfson M, Wilkinson ST. Changes in pharmacotherapeutic approaches in the treatment of bipolar disorder by primary care physicians. General Hospital Psychiatry 2020, 67: 141-143. PMID: 32184005, DOI: 10.1016/j.genhosppsych.2020.03.002.Peer-Reviewed Original Research
2019
Psychotropic polypharmacy reconsidered: Between-class polypharmacy in the context of multimorbidity in the treatment of depressive disorders
Rhee TG, Rosenheck RA. Psychotropic polypharmacy reconsidered: Between-class polypharmacy in the context of multimorbidity in the treatment of depressive disorders. Journal Of Affective Disorders 2019, 252: 450-457. PMID: 31004825, PMCID: PMC6520147, DOI: 10.1016/j.jad.2019.04.018.Peer-Reviewed Original ResearchConceptsPsychotropic polypharmacyDepressive disorderDepressed adultsPsychiatric careNational Ambulatory Medical Care SurveyPsychiatric multimorbidityAmbulatory Medical Care SurveyPrevalence of polypharmacyAdjunctive treatment strategyMore psychotropic medicationsOutpatient psychiatric careContext of multimorbidityPrescription combinationsPsychiatric polypharmacyPsychotropic classesPsychotropic medicationsCare SurveyPolypharmacyTreatment strategiesMultimorbidityAdultsCareAntipsychoticsAntidepressantsDisorders
2018
Initiation of new psychotropic prescriptions without a psychiatric diagnosis among US adults: Rates, correlates, and national trends from 2006 to 2015
Rhee TG, Rosenheck RA. Initiation of new psychotropic prescriptions without a psychiatric diagnosis among US adults: Rates, correlates, and national trends from 2006 to 2015. Health Services Research 2018, 54: 139-148. PMID: 30334247, PMCID: PMC6338322, DOI: 10.1111/1475-6773.13072.Peer-Reviewed Original ResearchConceptsNational Ambulatory Medical Care SurveyPrimary care visitsNewer psychotropic medicationsPsychiatric diagnosisPsychotropic prescriptionsCare visitsPsychotropic medicationsUS adultsAmbulatory Medical Care SurveyNational trendsNon-psychiatric specialistsPsychotropic drug prescriptionNon-psychiatrist physiciansLogistic regression analysisTimes greater oddsRepeated cross-sectional designCross-sectional designOutpatient settingCare SurveyClinical correlatesDrug prescriptionsOutpatient careLower oddsGreater oddsPrevention websiteAntipsychotic Prescriptions Among Adults With Major Depressive Disorder in Office-Based Outpatient Settings: National Trends From 2006 to 2015.
Rhee TG, Mohamed S, Rosenheck RA. Antipsychotic Prescriptions Among Adults With Major Depressive Disorder in Office-Based Outpatient Settings: National Trends From 2006 to 2015. The Journal Of Clinical Psychiatry 2018, 79: 17m11970. PMID: 29469245, PMCID: PMC5932223, DOI: 10.4088/jcp.17m11970.Peer-Reviewed Original ResearchConceptsMajor depressive disorderAntipsychotic prescribingAntipsychotic prescriptionsDepressive disorderNational Ambulatory Medical Care SurveyOffice-based outpatient visitsAmbulatory Medical Care SurveyMultivariable logistic regression analysisMore concomitant medicationsNext-step therapyNext-step treatmentsAdults 75 yearsLogistic regression analysisLong-term effectivenessGreater long-term effectivenessConcomitant medicationsClinical factorsAntipsychotic useOutpatient visitsAntipsychotic treatmentOutpatient settingCare SurveyMental health counselingAntipsychotic agentsDiagnosis of cannabis